Supporters worldwide are gearing up to celebrate Fragile X Awareness Month, an initiative held each July to boost recognition of…
Articles by Lindsey Shapiro, PhD
Long-term, daily treatment with the investigational cannabidiol (CBD) gel ZYN002 — also known as Zygel — led to clinically…
A single dose of Spinogenix’s investigational oral therapy SPG601 led to significant reductions in a measure of abnormal brain…
Patients, caregivers, and professionals will gather next month at the National Fragile X Foundation‘s (NFXF) 19th International Fragile X…
The U.S. Food and Drug Administration (FDA) has given Spinogenix the green light for a Phase 2 clinical trial…
The LivJoy Foundation is funding a four-year postdoctoral research fellowship for an early career scientist at the University of…
Researchers in Egypt have uncovered two biomarkers that could help identify fragile X syndrome where genetic testing is not…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation to zatolmilast, Tetra Therapeutics’ investigational…
Allos Pharma has met with the U.S. Food and Drug Administration (FDA) to optimize the design of a planned…
Long-term treatment with Zygel, Zynerba Pharmaceuticals’ experimental cannabidiol (CBD) gel, is tolerated well and leads to clinically meaningful behavioral…